Is There a Need for "Triple Therapy"? Role of Anticoagulation with Dual Antiplatelet Therapy in Acute Coronary Syndromes (ATLAS Study & TRAP Study)

被引：6

作者：

Patrick, William L. ^{[1
]}

Patel, Charmaine ^{[1
]}

Guddeti, Raviteja ^{[1
]}

Narayan, Aarti ^{[1
]}

Maddaleni, Michael ^{[1
]}

Kumar, Shankar ^{[1
]}

Dolma, Kalsang ^{[1
]}

Serla, Vishnu Vardhan ^{[1
]}

Sangha, Maheep ^{[1
]}

Govindavarjhulla, Aditya ^{[1
]}

Saddala, Prashanth ^{[1
]}

Singh, Priyamvada ^{[1
]}

Halaby, Rim ^{[1
]}

Gibson, C. Michael ^{[1
]}

机构：

[1] Harvard Univ, Beth Israel Deaconess Med Ctr, PERFUSE Study Grp, Cardiovasc Div,Dept Med,Sch Med, Boston, MA 02215 USA

来源：

CURRENT CARDIOLOGY REPORTS | 2013年 / 15卷 / 10期

关键词：

Acute coronary syndrome; Triple therapy; Anticoagulation; Dual antiplatelet therapy; Factor Xa inhibition; Rivaroxaban; ATLAS; ST-SEGMENT ELEVATION; MYOCARDIAL-INFARCTION; ARTERY-DISEASE; DOUBLE-BLIND; CLOPIDOGREL; ASPIRIN; TRIAL; RIVAROXABAN; PREVENTION; EVENTS;

D O I：

10.1007/s11886-013-0411-1

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In the past two decades there has been a succession of advances in the development of anticoagulant and antiplatelet therapies to be used in the treatment of ACS. Despite optimal dual antiplatelet therapy, nearly 10-12 % of patients still face a risk of death or myocardial infarction one year following PCI. This large residual risk provides the impetus for the development of more effective strategies. Dual pathway regimens that combine antiplatelets (aspirin and a thienopyridine), along with an anticoagulant such as rivaroxaban may prove to be a therapeutic option in patients with ACS.

引用

页数：7

共 29 条

[1] Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome
Alexander, John H.
Lopes, Renato D.
James, Stefan
Kilaru, Rakhi
He, Yaohua
Mohan, Puneet
Bhatt, Deepak L.
Goodman, Shaun
Verheugt, Freek W.
Flather, Marcus
Huber, Kurt
Liaw, Danny
Husted, Steen E.
Lopez-Sendon, Jose
De Caterina, Raffaele
Jansky, Petr
Darius, Harald
Vinereanu, Dragos
Cornel, Jan H.
Cools, Frank
Atar, Dan
Luis Leiva-Pons, Jose
Keltai, Matyas
Ogawa, Hisao
Pais, Prem
Parkhomenko, Alexander
Ruzyllo, Witold
Diaz, Rafael
White, Harvey
Ruda, Mikhail
Geraldes, Margarida
Lawrence, Jack
Harrington, Robert A.
Wallentin, Lars
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (08) : 699 - 708
[2] Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial
Alexander, John H.
Becker, Richard C.
Bhatt, Deepak L.
Cools, Frank
Crea, Filippo
Dellborg, Mikael
Fox, Keith A. A.
Goodman, Shaun G.
Harrington, Robert A.
Huber, Kurt
Husted, Steen
Lewis, Basil S.
Lopez-Sendon, Jose
Mohan, Puneet
Montalescot, Gilles
Ruda, Mikhail
Ruzyllo, Witold
Verheugt, Freek
Wallentin, Lars
Darius, Harald
Simoons, Maarten
Boersma, Eric
DeLemos, James
Spencer, Fred
[J]. CIRCULATION, 2009, 119 (22) : 2877 - U39
[3] Optimal intensity of oral anticoagulant therapy after myocardial infarction
Azar, AJ
Cannegieter, SC
Deckers, JW
Briet, E
vanBergen, PFMM
Jonker, JJC
Rosendaal, FR
[J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1996, 27 (06) : 1349 - 1355
[4] Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71
[5] ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither
Baigent, C
Collins, R
Appleby, P
Parish, S
Sleight, P
Peto, R
[J]. BMJ-BRITISH MEDICAL JOURNAL, 1998, 316 (7141): : 1337 - 1343
[6] Effects of rivaroxaban, acetylsalicylic acid and clopidogrel as monotherapy and in combination in a porcine model of stent thrombosis
Becker, E. M.
Perzborn, E.
Klipp, A.
Luecker, C.
Buetehorn, U.
Kast, R.
Badimon, J. J.
Laux, V.
[J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2012, 10 (12) : 2470 - 2480
[7] Brummel-Ziedins K, 2008, J THROMB HAEMOST, V6, P104
[8] Cavender MA, 2013, J AM COLL CARDIOL, P61
[9] COOL DE, 1985, J BIOL CHEM, V260, P3666
[10] DAVIES MJ, 1992, CIRCULATION, V85, P19

← 1 2 3 →